TERIPARATIDE
GrowthPeptideteriparatide
NDASUBCUTANEOUSSOLUTION
Approved
Jun 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Clinical Trials (5)
A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism
Started Apr 2026
36 enrolled
HypoparathyroidismEndocrine System DiseasesParathyroid Diseases
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
Started Feb 2026
50 enrolled
Hypoparathyroidism
A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)
Started Jan 2026
10 enrolled
Hypoparathyroidism
Fracture Recovery for Returning to Duty (Teriparatide STRONG)
Started Dec 2022
183 enrolled
Stress Fracture of Tibia or Fibula
Study and Follow-up of the Clinical Effectiveness and Comparative Safety of Biosimilar Teriparatide in the Management of Postmenopausal or Senile.
Started Jun 2021